Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity
- PMID: 15218053
- DOI: 10.1189/jlb.0104034
Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity
Abstract
Synthetic phosphorothioate oligodeoxynucleotides (ODN) bearing unmethylated CpG motifs can mimic the immune-stimulatory effects of bacterial DNA and are recognized by Toll-like receptor 9 (TLR9). Past studies have demonstrated that nucleotide modifications at positions at or near the CpG dinucleotides can severely affect immune modulation. However, the effect of nucleotide modifications to stimulate human leukocytes and the mechanism by which chemically modified CpG ODN induce this stimulation are not well understood. We investigated the effects of CpG deoxyguanosine substitutions on the signaling mediated by human TLR9 transfected into nonresponsive cells. ODN incorporating most of these substitutions stimulated detectable TLR9-dependent signaling, but this was markedly weaker than that induced by an unmodified CpG ODN. One of the most active ODN tested contained deoxyinosine for deoxyguanosine substitutions (CpI ODN), but its relative activity to induce cytokine secretion on mouse cells was much weaker than on human cells. The activity was dependent on TLR9, as splenocytes from mice genetically deficient in TLR9 did not respond to CpI ODN stimulation. It is surprising that CpI ODN were nearly as strong as CpG ODN for induction of human B cell stimulation but were inferior to CpG ODN in their ability to induce T helper cell type 1 effects. These data indicate that certain deoxyguanosine substitutions in CpG dinucleotides are tolerated to stimulate a TLR9-mediated immune response, but this response is insufficient to induce optimal interferon-alpha-mediated effects, which depend on the presence of an unmodified CpG dinucleotide. These studies provide a structure-activity relationship for TLR9 agonist compounds with diverse immune effects.
Similar articles
-
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.Eur J Immunol. 2004 Jan;34(1):251-62. doi: 10.1002/eji.200324032. Eur J Immunol. 2004. PMID: 14971051
-
Augmentation of T(H)-1 type response by immunoactive AT oligonucleotide from lactic acid bacteria via Toll-like receptor 9 signaling.Biochem Biophys Res Commun. 2005 Jan 28;326(4):782-7. doi: 10.1016/j.bbrc.2004.11.119. Biochem Biophys Res Commun. 2005. PMID: 15607737
-
Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.Immunology. 2004 Oct;113(2):212-23. doi: 10.1111/j.1365-2567.2004.01962.x. Immunology. 2004. PMID: 15379982 Free PMC article.
-
Bovine toll-like receptor 9: a comparative analysis of molecular structure, function and expression.Vet Immunol Immunopathol. 2005 Oct 18;108(1-2):11-6. doi: 10.1016/j.vetimm.2005.07.012. Vet Immunol Immunopathol. 2005. PMID: 16098606 Review.
-
Recent advances in the development of immunostimulatory oligonucleotides.Curr Opin Drug Discov Devel. 2003 Mar;6(2):204-17. Curr Opin Drug Discov Devel. 2003. PMID: 12669456 Review.
Cited by
-
Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium.Clin Exp Immunol. 2005 Aug;141(2):298-306. doi: 10.1111/j.1365-2249.2005.02848.x. Clin Exp Immunol. 2005. PMID: 15996194 Free PMC article.
-
Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment.Int J Mol Sci. 2019 Aug 29;20(17):4224. doi: 10.3390/ijms20174224. Int J Mol Sci. 2019. PMID: 31470511 Free PMC article. Review.
-
Toll-like receptor 9: a new target of ischemic preconditioning in the brain.J Cereb Blood Flow Metab. 2008 May;28(5):1040-7. doi: 10.1038/sj.jcbfm.9600606. Epub 2008 Jan 9. J Cereb Blood Flow Metab. 2008. PMID: 18183029 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous